Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-111 in Acute Unilateral Vestibulopathy
2016-003927-45Phase 2Completed
- Sponsor
- Sensorion
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seliforant in vestibular neuritis (3 arms), sponsored by Sensorion. Primary endpoint: Vertigo intensity AUC in standing position over 4 treatment days. Started Mar 2017; status: completed.
02
Drugs
seliforant
03
Conditions
vestibular neuritis
Beyond the preview
Go deeper on 2016-003927-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003927-45.